Century Health Raises $5M for CHARM AI Platform to Accelerate Life Sciences Research

Why It Matters

By turning fragmented EHR text into high‑quality, regulatory‑grade real‑world evidence, Century Health speeds up research pipelines and reduces costly manual chart review, a critical advantage for biopharma in a data‑starved market.

Key Takeaways

• Seed round raised $5M, led by Origin Ventures
• CHARM AI achieves 97% accuracy on unstructured EHR data
• Provider network grew 60x, adding neurology, nephrology, ophthalmology
• Top five pharma companies already deployed the abstraction platform
• EHR spending freezes push hospitals toward AI‑driven data solutions

Pulse Analysis

The life‑sciences sector is confronting a data wall as publicly available biomedical datasets become exhausted. Researchers now depend on real‑world evidence (RWE) drawn from electronic health records, yet up to 80% of that information remains locked in free‑form notes and reports. This scarcity has shifted the competitive edge from raw compute power to the ability to harvest, clean, and structure clinical data at scale, prompting biopharma to seek specialized AI solutions that can deliver regulatory‑grade datasets quickly and reliably.

Century Health’s CHARM (Century Health Abstraction & Retrieval Model) directly addresses this bottleneck. Leveraging proprietary natural‑language processing, CHARM extracts diagnoses, lab results, and treatment timelines from unstructured EHRs with a 97% accuracy rate verified against clinical experts. The platform’s rapid scaling is underpinned by a 60‑fold expansion of its provider network, now covering high‑value therapeutic areas such as neurology, nephrology, ophthalmology and immunology. Early adoption by multiple top‑five pharmaceutical firms demonstrates market validation, as these partners use CHARM‑generated RWE to refine disease models, stratify patients for trials, and substantiate safety claims for regulatory submissions.

The $5 million seed injection, led by Origin Ventures and supported by a cohort of health‑tech investors, positions Century Health to capitalize on the broader industry shift away from in‑house AI development toward vendor‑driven vertical automation. As hospitals curb legacy EHR spending and life‑science executives prioritize ROI‑focused AI collaborations, platforms that can turn fragmented clinical text into actionable evidence will command premium valuations. Century Health’s blend of high‑accuracy AI, deep specialty data, and pharma partnerships suggests it could become a cornerstone infrastructure for the next generation of drug development, accelerating time‑to‑market and delivering tangible cost savings across the healthcare ecosystem.